<a href="https://www.fiercebiotech.com/medtech/pulnovo-medical-scores-100m-oversubscribed-finance-round-led-medtronic" hreflang="en">Pulnovo Medical scores $100M in finance round led by Medtronic</a>
Pulnovo Medical, a Chinese medtech company specializing in treatments for pulmonary hypertension and heart failure, secured $100 million in a financing round led by Medtronic to advance its clinical development and global commercialization efforts. The funding will support the company's innovative Pulmonary Artery Denervation system, which targets key mechanisms of cardiopulmonary disease.
Pulnovo Medical's $100 million financing round led by Medtronic signals a significant investment opportunity in the field of minimally invasive therapies for pulmonary hypertension and heart failure. This strategic move highlights the potential growth of Pulnovo’s Pulmonary Artery Denervation system, which is advancing toward global commercialization and regulatory approvals. As a professional tracking healthtech investments, consider the implications of this financing round and the partnership with Medtronic for expanding Pulnovo's market reach and enhancing their technological capabilities.